 | |
| Clinical data | |
|---|---|
| Trade names | Celontin |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a682028 |
| Routes of administration | By mouth (capsules) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Hepatic (demethylation andglucuronidation) |
| Metabolites | N-desmethylmethosuximide |
| Eliminationhalf-life | 1.4–2.6 hours(mesuximide) 28–38 hours(active metabolite) |
| Excretion | Urine |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.000.934 |
| Chemical and physical data | |
| Formula | C12H13NO2 |
| Molar mass | 203.241 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
 N Y (what is this?) (verify) | |
Mesuximide (ormethsuximide,methosuximide) is asuccinimideanticonvulsant medication. It is sold as aracemate byPfizer under the tradenamesPetinutin (Switzerland)[1] andCelontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite,N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]
The medical use is indicated for the control ofabsence seizures that are refractory to other drugs.[2]
 | Thisanticonvulsant-related article is astub. You can help Wikipedia byexpanding it. |